ID,LABEL,Parent,Parent (name),inSubset,Equivalent Class,realized in,has member,has quality,has role,characteristic of,is about,mentions,part of,realized in,axioms,definition,definition source,term editor,alternative label,editor note,comment,term tracker item
ID,A rdfs:label,C %,,A http://www.geneontology.org/formats/oboInOwl#inSubset,EC %,C 'realized in' some % SPLIT=|,C 'has member' some % SPLIT=|,C 'has quality' some % SPLIT=|,C 'has role' some % SPLIT=|,C 'characteristic of' some % SPLIT=|,C 'is about' some % SPLIT=|,C mentions some % SPLIT=|,C 'part of' some % SPLIT=|,C 'realized in' some % SPLIT=|,C %,A definition,A definition source SPLIT=|,A term editor SPLIT=|,A alternative label SPLIT=|,A editor note SPLIT=|,A rdfs:comment SPLIT=|,A term tracker item SPLIT=|
VO:0007653,HPV associated cancer,DOID:162,cancer,disposition,('cancer' and 'disease has basis in' some 'HPV infection'),,,,,,,,,,('disease has basis in' some 'HPV infection'),"A cancer that is caused by human papillomavirus (HPV) infection. HPV infection can lead to six types of cancer including anal, cervical, oropharyngeal, penile, vaginal, and vulvar cancer.",,Jie Zheng|Xingxian Li|Anna Maria Masci,,"placeholder, will send new term requst to DOID",,https://github.com/vaccineontology/VO/issues/677
VO:0000207,vaccine contraindication,OAE:0000055,contraindication,disposition,,,,,,,,,,,,A vaccine contraindication is a contraindication that increases the risks of a vaccination. ,,Oliver He,contraindication for vaccination,,,
VO:0000266,fungal disease,DOID:4,disease,disposition,,,,,,,,,,,,,,Oliver He,,,,
VO:0000713,vaccine allergen disposition,BFO:0000016,disposition,disposition,,,,,,,,,,,,,,Oliver He,,,,
VO:0000278,vaccine function,BFO:0000034,function,disposition,'preventive vaccine function' or 'therapeutic vaccine function',,,,,,,,,,,To induce or modify protective or therapeutic immune response against a disease.,,Oliver He|Melanie Courtot|Allen Xiang|Alan Ruttenburg|Barry Smith|Jie Zheng|Anna Maria Masci,,"PERSPN: Oliver He: There has been hot discussion about whether we use 'vaccine function' or 'vaccine role'. Vaccine role may not be the good term to use. Vaccine is designed to be 'vaccine', so it should be vaccine function. One special case is cowpox virus. The cowpox virus can be mixed with some liquid like water and used as a smallpox vaccine. In this case, people often say: the cowpox virus has a 'vaccine role'. However, the cowpox virus vaccine is a processed material of a mix of the virus with water. The virus is a virus, it is not a vaccine per se. Therefore, vaccine role may not be an accurate term.",,
VO:0000225,hypersensitivity to neomycin,VO:0000224,hypersensitivity to antibiotic,disposition,,,,,,,,,,,,,,Oliver He,,,,
VO:0000226,hypersensitivity to polymyxin,VO:0000224,hypersensitivity to antibiotic,disposition,,,,,,,,,,,,,,Oliver He,,,,
VO:0000237,hypersensitivity to gentamicin,VO:0000224,hypersensitivity to antibiotic,disposition,,,,,,,,,,,,,,Oliver He,,,,
VO:0000218,hypersensitivity to chicken egg,VO:0000213,hypersensitivity to chicken product,disposition,,,,,,,,,,,,,,Oliver He,,,,
VO:0000235,life-threatening reaction to previous influenza vaccination,VO:0000233,life-threatening reaction to previous vaccination,disposition,,,,,,,,,,,,,,Oliver He,,,,
VO:0000233,life-threatening reaction to previous vaccination,VO:0000227,reaction to previous vaccination,disposition,,,,,,,,,,,,,,Oliver He,,,,
VO:0000213,hypersensitivity to chicken product,VO:0000207,vaccine contraindication,disposition,,,,,,,,,,,,,,Oliver He,,,,
VO:0000224,hypersensitivity to antibiotic,VO:0000207,vaccine contraindication,disposition,,,,,,,,,,,,,,Oliver He,,,,
VO:0000227,reaction to previous vaccination,VO:0000207,vaccine contraindication,disposition,,,,,,,,,,,,,,Oliver He,,,,
VO:0000240,hypersensitity to gelatin,VO:0000207,vaccine contraindication,disposition,,,,,,,,,,,,,,Oliver He,,,,
VO:0000244,hypersensitity to arginine,VO:0000207,vaccine contraindication,disposition,,,,,,,,,,,,,,Oliver He,,"Arginine is a conditionally essential amino acid, meaning most of the time it can be manufactured by the human body, and does not need to be obtained directly through the diet. The biosynthetic pathway however does not produce sufficient arginine, and some must still be consumed through diet. Individuals who have poor nutrition or certain physical conditions may be advised to increase their intake of foods containing arginine. Infants are unable to meet their requirements and thus arginine is nutritionally essential for infants.",,
VO:0000248,history of asthma,VO:0000207,vaccine contraindication,disposition,,,,,,,,,,,,,,Oliver He,,,,
VO:0000255,usage of bronchodilator,VO:0000207,vaccine contraindication,disposition,,,,,,,,,,,,,,Oliver He,,,,
VO:0000261,usage of steroid,VO:0000207,vaccine contraindication,disposition,,,,,,,,,,,,,,Oliver He,,,,
VO:0000452,preventive vaccine function,VO:0000278,vaccine function,disposition,,disorder prevention|induction of adaptive immune response to antigen|vaccination,,,,,,,,disorder prevention|induction of adaptive immune response to antigen|vaccination,,A vaccine function realized by the process of vaccination and leading to induction of an adaptive immune response to prevent a specific disorder.,,Oliver He|Jie Zheng,prophylactic vaccine function,,,
VO:0000562,therapeutic vaccine function,VO:0000278,vaccine function,disposition,,disorder treatment|vaccination,,,,,,,,disorder treatment|vaccination,,A vaccine function realized the process of vaccination and leading to induction of an adaptive immune response to treat an existing specific disorder.,,Oliver He|Jie Zheng,,,,
VO:0001089,CDC recommendation of the use of  Influenza A (h1N1) 2009 vaccine,IAO:0000001,conditional specification,information content entity,,,,,,,,,,,,,WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm,Oliver He|Allen Xiang,,,,
VO:0001160,vaccination dose specification,OBI:0000969,dose specification,information content entity,,,,,,,vaccination,,,,,,,Oliver He|Allen Xiang,,,,
VO:0001161,challenge dose specification,OBI:0000969,dose specification,information content entity,,,,,,,pathogen challenge,,,,,,,Oliver He|Allen Xiang,,,,
VO:0010288,study design variable,IAO:0000033,directive information entity,information content entity,(OBI:0000751 or OBI:0000750),,,,,,,,,,,A directive information entity that is part of a study design. It can be eithor independent variables whose values are selected to determine its relationship to an observed phenomenon (the dependent variable) or dependent variables that are studied and expected to change when the independent variable varies.,,Jie Zheng,,,,
VO:0001364,human immunization objective,VO:0000585,immunization objective,information content entity,,,,,,,,,,,,,,,,,,
VO:0010149,no vaccine administered,IAO:0000030,information content entity,information content entity,,,,,,,,,,,,An information content entity that specify no vaccine adminstered.,https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx,Jie Zheng,,,,
VO:0010229,reserved cvx code for not using,IAO:0000030,information content entity,information content entity,,,,,,,,,,,,An information content entity that specifies the CVX code that will not be used to avoid confusion with code 999.,https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx,Jie Zheng,RESERVED - do not use,,,
VO:0015077,drug brand name,IAO:0000030,information content entity,information content entity,,,,,,,,,,,,An information content entity that specifies a family of drug products containing a specific active ingredient.,https://www.nlm.nih.gov/research/umls/rxnorm/docs/appendix5.html,Jie Zheng,,,,
VO:0006019,Historical record of a typhus vaccination,IAO:0000030,information content entity,information content entity,,,,,,,,,,,,,,,typhus historical,,,
VO:0010395,flu season,IAO:0000030,information content entity,information content entity,,,,,,,,,,,,"A period typically associated with a higher incidence of influenza virus infections, characterized by the increased circulation of flu viruses in a population.","https://www.cdc.gov/flu/about/season/index.html#:~:text=While%20influenza%20viruses%20spread%20year,varies%20from%20season%20to%20season|https://www.cdc.gov/ncird/whats-new/flu-southern-hemisphere.html|PMID: 37535890",Jie Zheng|Xingxian Li|Ellen Zhang,,"Flu viruses circulate year-round, but most cases are typically reported during the fall and winter months, a period known as flu season (CDC, 2022). The seasonality of flu varies globally, influenced by the distinct seasonal patterns of each hemisphere. Therefore, the flu season in the Northern Hemisphere often spans two calendar years, while in the Southern Hemisphere, it generally occurs within a single year. In temperate climate zones, peak flu activity typically occurs from October to April in the Northern Hemisphere and from April to October in the Southern Hemisphere (CDC, 2023; Kakoullis et al., 2023). In the United States, the flu season typically peaks between December and February, according to the CDC (2022).",,
VO:0000055,vaccine related journal article,IAO:0000013,journal article,information content entity,,,,,,,,vaccine,,,,"A jourmal article that mentions a vaccine, which was retrieved from PubMed and annotated using VO-SciMinner.",PMID:21871085,Asiyah Yu Lin,,,,
VO:0010261,vaccine study design,OBI:0500000,study design,information content entity,,,,,,,,,,,,A study design that is about a vaccine study.,,Anthony Huffman,,,,
VO:0000585,immunization objective,IAO:0000005,objective specification,information content entity,,,,,,,,,,,,immunization objective is the specification of an objective to achieve immunization.,WEB: http://en.wikipedia.org/wiki/Immunization,Oliver He|Allen Xiang,,,,
VO:0001257,prevention of disorder objective,IAO:0000005,objective specification,information content entity,,,,,,,,,,,,The specification of an objective to prevent a disorder.,,Oliver He,,,,
VO:0001258,amelioration of disorder objective,IAO:0000005,objective specification,information content entity,,,,,,,,,,,,The specification of an objective to ameliorate  a disorder.,,Oliver He,,,,
VO:0001479,vaccine target specification,IAO:0000005,objective specification,information content entity,,,,,,,,,,,,The objective that intends to produce vaccine via the vaccine preparation process.,,Oliver He,,,,
VO:0001162,specification of vaccination-challenge interval,IAO:0000104,plan specification,information content entity,,,,,,,,,,,,specification of time interval after vaccination for challenge is a plan specification that specifies the time interval after vacciation for challenge,,Oliver He|Allen Xiang,,,,
VO:0000572,vaccination protocol,OBI:0000272,protocol,information content entity,,,,,,,vaccination,,,,,vaccination protocol is the protocol of a vaccination procedure.,,Oliver He,vaccination schedule,,,
VO:0001163,pathogen challenge protocol,OBI:0000272,protocol,information content entity,,,,,,,,,,,,pathogen challenge protocol is a protocol that is used for a pathogen challenge process.,,Oliver He|Allen Xiang,,,,
VO:0010150,record of unknown vaccine or immune globulin,OBI:0000852,record of missing knowledge,information content entity,,,,,,,,,,,,A record of missing knowledge indicating that vaccine or immune globulin is unknown.,https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx,Jie Zheng,unknown vaccine or immune globulin,,,
VO:0010126,host species variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the species of the host used for a study.,PMID:29485622,Anthony Huffman,,,,
VO:0010129,host disease state variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,"A variable representing the host's participation in a disease state (i.e. healthy, or diabetic).",PMID:32516066,Anthony Huffman,,,,
VO:0010130,host sex variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the biological sex of the host,PMID:29485622,Anthony Huffman,,,,
VO:0010131,host age variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the age of the host,PMID:32347787,Anthony Huffman,,,,
VO:0010132,host pregnancy variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the presence of another developing organism in an animal host,PMID:34082643,Anthony Huffman,,,,
VO:0010134,host comorbidity variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing host quality's that leads to a wore outcome to vaccination or pathogen disease state.,PMID:32516066,Anthony Huffman,,,,
VO:0010145,host pathogen exposure variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the prior immungenic memory a host has against a specific pathogen,PMID:32668444,Anthony Huffman,,,,
VO:0010234,host lineage variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,"A variable representing the lineage (breed, ethnicity) of the animal host",PMID:35469999,Anthony Huffman,,,,
VO:0010235,vaccination-challenge interval variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the interval between vaccination and pathogen challenge,PMID:34328699,Anthony Huffman,,,,
VO:0010236,intevention interval variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the interval between the vaccination and pathogen challenge start,PMID:34328699,Anthony Huffman,,,,
VO:0010237,challenge-killing interval variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the interval between the pathogen challenge start and end,PMID:34328699,Anthony Huffman,,,,
VO:0010238,challenge admistration route,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the administration route of the pathogen challenge,PMID:34328699,Anthony Huffman,,,,
VO:0010239,sacrifice process variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the planned process used for the sacrifice,PMID:34328699,Anthony Huffman,,,,
VO:0010240,host adverse event variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the presence of host adverse events from the vaccination process.,PMID:34153517,Anthony Huffman,,,,
VO:0010241,assay mesurement variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the measurement used for an assay,PMID:29485622,Anthony Huffman,,,,
VO:0010242,assay sample endpoint variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the timepoint a biological sample was taken after vaccination,PMID:29485622,Anthony Huffman,,,,
VO:0010243,assay type variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,"A variable representing the assay type (ELISA, microarray) etc.",PMID:29485622,Anthony Huffman,,,,
VO:0010244,assay analysis tool version variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the programs used to analyze an assay,PMID:29485622,Anthony Huffman,,,,
VO:0010245,assay sample source variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the tissue or source of sample used for an assay.,PMID:29485622,Anthony Huffman,,,,
VO:0010246,assay platform variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,"A variable representing the assay platform used (Nanopore,) etc.",PMID:29485622,Anthony Huffman,,,,
VO:0010247,pathogen variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the species or type of the pathogen,PMID:29485622,Anthony Huffman,,,,
VO:0010248,pathogen strain variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the lineage of pathogen strain (incljuding presence or absence of virulence factors),PMID:24259431,Anthony Huffman,,,,
VO:0010249,pathogen attenuation variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the presence of an attenuation process (killed microbe) on a pathogen challenge,PMID:29485622,Anthony Huffman,,,,
VO:0010250,host vaccination frequency variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the host vaccination frequency etc.,PMID:29485622,Anthony Huffman,,,,
VO:0010251,vaccination route variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the vaccination route etc.,PMID:24259431,Anthony Huffman,,,,
VO:0010252,vaccination dose variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing dose representing the vaccination ,PMID:34328699,Anthony Huffman,,,,
VO:0010253,vaccination frequency variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable represting the number of occurences a vaccination was administered,PMID:24259431,Anthony Huffman,,,,
VO:0010254,vaccination interval variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the interval between multiple vaccinations.,PMID:24259431,Anthony Huffman,,,,
VO:0010255,vaccine target variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,"A variable representing the vaccine target (pathogen, disease) etc.",PMID:24259431,Anthony Huffman,,,,
VO:0010256,vaccine antigen variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,"A variable representing the vaccine antigen (SARS-CoV-2 protein, whole organism) etc.",PMID:24259431,Anthony Huffman,,,,
VO:0010257,vaccine adjuvant variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the vaccine adjuvant (silver) etc.,PMID:24259431,Anthony Huffman,,,,
VO:0010258,vaccine vector variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,"A variable representing the vaccine vector (DNA plasmid, viral vector) etc.",PMID:24259431,Anthony Huffman,,,,
VO:0010259,vaccine preservative variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A variable representing the vaccine preservative ,PMID:24259431,Anthony Huffman,,,,
VO:0010260,vaccine study design variable,VO:0010288,study design variable,information content entity,,,,,,,,,,,,A study design variable that is used in a vaccine study.,,Anthony Huffman,,,,
VO:0000453,prime boost regimen,VO:0000572,vaccination protocol,information content entity,,,,,,,,,,,,,,Oliver He,,,,
VO:0010262,host response to vaccine study design,VO:0010261,vaccine study design,information content entity,,,,,,,,,,,,A vaccine study design that is about the host response to a vaccine.,,Anthony Huffman,,,,
VO:0010263,vaccine challenge study design,VO:0010261,vaccine study design,information content entity,,,,,,,,,,,,A vaccine study design that is about the vaccine challenge to a host.,,Anthony Huffman,,,,
VO:0000811,vaccine epitope,OBI:1110034,antigen,material entity,,,,,,,,,,,,,,Oliver He,,,,
VO:0000907,surface antigens from the zona pellucida,OBI:1110034,antigen,material entity,,,,,,,,,,,,,,Oliver He,,,,
VO:0001232,protective antigen,OBI:1110034,antigen,material entity,('antigen' and 'has role' some 'protective antigen role'),,,,protective antigen role,,,,,,,,,Oliver He|Allen Xiang,,,,
VO:0007655,tumor antigen,OBI:1110034,antigen,material entity,('tumor-specific antigen' or 'tumor-associated antigen'),,,,,,,,,,,Either a tumor-specific or a tumor-associated antigen.,,Jie Zheng|Anna Maria Masci|Oliver He|Barry Smith,,,,https://github.com/vaccineontology/VO/issues/677
VO:0000486,chicken ovalbumin egg protein allergen,VO:0000912,chicken egg protein allergen,material entity,,,,,,,,,,,,"A chicken egg protein allergen where the protein allergen is ovalbumin, the main protein found in egg write, making up 60-65% of the total protein.",WEB: http://en.wikipedia.org/wiki/Ovalbumin,Oliver He,,,,
VO:0015062,injectable product,VO:0015061,drug dose form,material entity,,,,,,,,,,,,,,Jie Zheng,,,,
VO:0015075,intramuscular solution,VO:0015061,drug dose form,material entity,,,,,,,,,,,,,,Jie Zheng,,,,
VO:0018843,oral,VO:0015061,drug dose form,material entity,,,,,,,,,,,,,,Jie Zheng,,,,
VO:0018844,oral suspension,VO:0015061,drug dose form,material entity,,,,,,,,,,,,,,Jie Zheng,,,,
VO:0018845,powder for oral suspension,VO:0015061,drug dose form,material entity,,,,,,,,,,,,,,Jie Zheng,,,,
VO:0018846,oral capsule,VO:0015061,drug dose form,material entity,,,,,,,,,,,,,,Jie Zheng,,,,
VO:0018847,oral tablet,VO:0015061,drug dose form,material entity,,,,,,,,,,,,,,Jie Zheng,,,,
VO:0019097,oral product,VO:0015061,drug dose form,material entity,,,,,,,,,,,,,,Jie Zheng,,,,
VO:0019098,pill,VO:0015061,drug dose form,material entity,,,,,,,,,,,,,,Jie Zheng,,,,
VO:0019100,nasal spray,VO:0015061,drug dose form,material entity,,,,,,,,,,,,,,Jie Zheng,,,,
VO:0019101,oral liquid product,VO:0015061,drug dose form,material entity,,,,,,,,,,,,,,Jie Zheng,,,,
VO:0000972,LHRH,FMA:12278,Hormone,material entity,,,,,,,,,,,,,,Oliver He,luteinizing hormone-releasing hormone,,,
VO:0001080,Androstenedione,FMA:12278,Hormone,material entity,,,,,,,,,,,,,,Oliver He,,,,
VO:0000554,human vaccinee at age 2-17 years old,VO:0000544,human vaccinee,material entity,,,,,,,,,human vaccinee at age 2-17 years old,,,,,,,,,
VO:0000548,human vaccinee population at age 2-17 years old,VO:0000545,human vaccinee population,material entity,,,human vaccinee at age 2-17 years old,,,,,,,,,,,,,,,
VO:0007654,HPV infection,IDO:0000586,infection,material entity,,,,,,,,,,,,An infection that has as part organisms of the human papillomavirus (HPV).,,Jie Zheng,,,,https://github.com/vaccineontology/VO/issues/677
VO:0015065,prefilled syringe,VO:0015062,injectable product,material entity,,,,,,,,,,,,,,Jie Zheng,,,,
VO:0015072,injectable suspension,VO:0015062,injectable product,material entity,,,,,,,,,,,,,,Jie Zheng,,,,
VO:0015073,injectable solution,VO:0015062,injectable product,material entity,,,,,,,,,,,,,,Jie Zheng,,,,
VO:0015074,injection form,VO:0015062,injectable product,material entity,,,,,,,,,,,,,,Jie Zheng,injection,,,
VO:0000545,human vaccinee population,VO:0000546,vaccinee population,material entity,,,human vaccinee,,,,,,,,,a population of human beings who are vaccinated.,,,,,,https://github.com/vaccineontology/VO/issues/630
VO:0000910,vaccine allergen,BFO:0000040,material entity,material entity,('material entity' and 'has disposition' some 'vaccine allergen disposition'),,,,,,,,,,('has disposition' some 'vaccine allergen disposition'),vaccine allergen is a material entity that is capable of stimulating a type-I hypersensitivity reaction in atopic individuals who has been vaccinated with a vaccine.,WEB: http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf,Oliver He|Allen Xiang,,,,
VO:0003030,gelatin,BFO:0000040,material entity,material entity,,,,,,,,,,,,"Gelatin is a mixture of peptides and proteins produced by partial hydrolysis of collagen extracted from the skin, boiled crushed bones, connective tissues, organs and some intestines of animals such as domesticated cattle, chicken, and pigs.(wikipedia)",,Asiyah Yu Lin,,,,
VO:0015061,drug dose form,BFO:0000040,material entity,material entity,,,,,,,,,,,,A material entity of a drug based on their general physical form and how they are administered.,https://www.nlm.nih.gov/research/umls/rxnorm/docs/appendix3.html,Jie Zheng,dose form group,,,
VO:0015076,drug package,BFO:0000040,material entity,material entity,,,,,,,,,,,,,,Jie Zheng,,,,
VO:0000560,toxin,CHEBI:23367,molecular entity,material entity,,,,,,,,,,,,A toxin is a poisonous substance produced within living cells or organisms; man-made substances created by artificial processes are thus excluded. ,,Oliver He,,,"The term was first used by organic chemist Ludwig Brieger (1849-1919).[3]
For a toxic substance not produced within living organisms, ""toxicant"" and ""toxics"" are also sometimes used.[citation needed].
Toxins can be small molecules, peptides, or proteins that are capable of causing disease on contact with or absorption by body tissues interacting with biological macromolecules such as enzymes or cellular receptors. Toxins vary greatly in their severity, ranging from usually minor and acute (as in a bee sting) to almost immediately deadly (as in botulinum toxin).-- from Wikipedia.
",
VO:0019099,delayed release oral capsule,VO:0018846,oral capsule,material entity,,,,,,,,,,,,,,Jie Zheng,,,,
VO:0019102,delayed release oral tablet,VO:0018847,oral tablet,material entity,,,,,,,,,,,,,,Jie Zheng,,,,
VO:0000299,company,OBI:0000245,organization,material entity,,,,,,,,,,,,A legal organization that represents an association of people with a specific objective.,https://en.wikipedia.org/wiki/Company,Oliver He,,,,
VO:0000546,vaccinee population,OBI:0000181,population,material entity,,,vaccinee,,,,,,,,,a population group that are vaccinated with a specific vaccine,,Oliver He,vaccinee group,,,https://github.com/vaccineontology/VO/issues/630
VO:0001094,pregnant women,OBI:0000181,population,material entity,,,,,,,,,,,,,WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm,Asiyah Yu Lin|Allen Xiang,,,,
VO:0001098,persons living with or providing care for infants aged <6 months,OBI:0000181,population,material entity,,,,,,,,,,,,,WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm,Asiyah Yu Lin|Allen Xiang,,,,
VO:0001099,health-care and emergency medical services personnel,OBI:0000181,population,material entity,,,,,,,,,,,,,WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm,Asiyah Yu Lin|Allen Xiang,,,,
VO:0001100,persons aged 6 months--24 years,OBI:0000181,population,material entity,,,,,,,,,,,,,WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm,Asiyah Yu Lin|Allen Xiang,,,,
VO:0001101,persons aged 25--64 years with  medical conditions at higher risk for influenza-related complications,OBI:0000181,population,material entity,,,,,,,,,,,,,WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm,Asiyah Yu Lin|Allen Xiang,,,,
VO:0000575,vaccine candidate,OBI:0000047,processed material,material entity,,,,,vaccine candidate role,,,,,,,vaccine candidate is a processed material that is designed to prevent or ameliorate a disorder in a target organism by modulating adaptive immune responses in that organism by administrating the vaccine.,,Oliver He|Alan Ruttenburg|Bjoern Peters|Lindsay Cowell|Melanie Courtot|Allen Xiang,,"During our call, we decided not to say vaccine candidate is an output of vaccine preparation, which may be reserved for vaccine alone. -- Aug 4, 2009.",,
VO:0001252,toxoid,OBI:0000047,processed material,material entity,,,,,,,,,,,,"is a bacterial toxin (usually an exotoxin) whose toxicity has been weakened or suppressed either by chemical (formalin) or heat treatment, while other properties, typically immunogenicity, are maintained.",WEB: http://en.wikipedia.org/wiki/Toxoid,Oliver He,,,,
VO:0010332,tumor-specific antigen,VO:0007655,tumor antigen,material entity,,,,,,,,,,,,Antigen that is only expressed by tumor cells.,,Jie Zheng|Anna Maria Masci|Oliver He|Barry Smith,,,,
VO:0010333,tumor-associated antigen,VO:0007655,tumor antigen,material entity,,,,,,,,,,,,Antigen that is overexpressed by tumor cells.,,Jie Zheng|Anna Maria Masci|Oliver He|Barry Smith,,,,
VO:0000912,chicken egg protein allergen,VO:0000910,vaccine allergen,material entity,,,,,,,,,,,,chicken egg protein allergen is a vaccine allergen that is composed of chicken egg protein.,,Oliver He|Allen Xiang|Melanie Courtot,,"Egg protein may come from NCIS thesaurus egg - poultry, combination
of minimal anatomy terminology and NCBI taxonomy... Eventually, this term chicken egg protein allergen may become a cross product of sevreal ontology terms.",,
VO:0000913,latex vaccine allergen,VO:0000910,vaccine allergen,material entity,,,,,,,,,,,,,,Oliver He|Allen Xiang,,,,
VO:0000915,gelatin vaccine allergen,VO:0000910,vaccine allergen,material entity,,,,,,,,,,,,,,Oliver He|Allen Xiang,,,,
VO:0000916,protamine sulfate vaccine allergen,VO:0000910,vaccine allergen,material entity,,,,,,,,,,,,,,Oliver He|Allen Xiang,,,,
VO:0000917,polymyxin B vaccine allergen,VO:0000910,vaccine allergen,material entity,,,,,,,,,,,,,,Oliver He|Allen Xiang,,,,
VO:0000011,vaccine B cell epitope,VO:0000811,vaccine epitope,material entity,,,,,,,,,,,,,,Oliver He,B cell epitope in vaccine,,,
VO:0000105,vaccine T cell epitope,VO:0000811,vaccine epitope,material entity,,,,,,,,,,,,,,Oliver He,T cell epitope in vaccine,,,
VO:0000238,vaccine dominant epitope,VO:0000811,vaccine epitope,material entity,,,,,,,,,,,,,,Oliver He,dominant epitope in vaccine,,,
VO:0000533,vaccine subdominant epitope,VO:0000811,vaccine epitope,material entity,,,,,,,,,,,,,,Oliver He,subdominant epitope in vaccine,,,
VO:0001090,vaccinee priority group,VO:0000546,vaccinee population,material entity,,,,,,,,,,,,A population group that have priority for  vaccination when a vaccine is first available.,,Oliver He|Allen Xiang,vaccination target group,,,
VO:0010463,humoral immune marker,OPMI:0000446,immune biomarker,material entity,,,,,,,,,,,,An immune biomarker that indicates a humoral immune response.,,Oliver He,,,,
VO:0010464,cell-mediated immune marker,OPMI:0000446,immune biomarker,material entity,,,,,,,,,,,,An immune biomarker that indicates a cell-mediated immune response.,,Oliver He,,,,
VO:0004869,HUMAN ADENOVIRUS E SEROTYPE 4 STRAIN CL-68578,NCBITaxon:10508,Adenoviridae,organism,,,,,,,,,,,,,http://purl.bioontology.org/ontology/RXNORM/1299785,,,,"CUI: C3159361|RXAUI: 4624424|TUI: T129, T121",
VO:0004871,HUMAN ADENOVIRUS B SEROTYPE 7 STRAIN 55142,NCBITaxon:10508,Adenoviridae,organism,,,,,,,,,,,,,http://purl.bioontology.org/ontology/RXNORM/1802483,,,,"CUI: C4083103|RXAUI: 8240118|TUI: T129, T121",
VO:0000333,Protozoa,NCBITaxon:2759,Eukaryota,organism,,,,,,,,,,,,"Protozoa are a diverse group of unicellular eukaryotic organisms,[1] many of which are motile. Originally, protozoa had been defined as unicellular protists with animal-like behavior, e.g., movement. Protozoa were regarded as the partner group of protists to protophyta, which have plant-like behaviour, e.g., photosynthesis.(http://en.wikipedia.org/wiki/Protozoa)",,Asiyah Yu Lin,,,,
VO:0000472,nontypeable Haemophilus influenzae,NCBITaxon:727,Haemophilus influenzae,organism,,,,,,,,,,,,"Nontypeable Haemophilus influenzae (NTHi) is a nonencapsulated Haemophilus influenzae (a gram-negative bacterium). It is the cause of a number of human respiratory tract diseases, such as otitis media, sinusitis, bronchitis, and pneumonia.",,Oliver He,NTHi,,,
VO:0000741,Haemophilus influenzae serotype b,NCBITaxon:727,Haemophilus influenzae,organism,,,,,,,,,,,,,,Oliver He,,,,
VO:0000051,Balb/c mouse,NCBITaxon:10090,Mus musculus,organism,,,,,,,,,,,,,,Oliver He,,,,
VO:0000506,vaccine organism,OBI:0100026,organism,organism,('organism' and 'has role' some 'vaccine component role'),,,,vaccine component role,,,,,,,an organism that is used as part of a vaccine,,Oliver He,,,,
VO:0001374,vaccinee,OBI:0100026,organism,organism,,,,,,,,,,,,an organism that is vaccinated with a vaccine,,Oliver He|Asiyah Yu Lin|Melanie Courtot,vaccinated organism,,,
VO:0001381,immunized organism,OBI:0100026,organism,organism,,,,,,,,,,,,an organism that is immunized for a disease,,Oliver He|Asiyah Yu Lin|Melanie Courtot,,,,
VO:0001383,unvaccinated organism,OBI:0100026,organism,organism,,,,,,,,,,,,an organism that is unvaccinated with a vaccine,,Oliver He|Asiyah Yu Lin|Melanie Courtot,,,,
VO:0000879,Porphyromonas denticanis,NCBITaxon:836,Porphyromonas,organism,,,,,,,,,,,,,,Oliver He,,,,
VO:0010460,SARS Coronavirus 2 XBB.1.5,NCBITaxon:2697049,Severe acute respiratory syndrome coronavirus 2,organism,,,,,,,,,,,,,,Jie Zheng,,,,
VO:0000126,live attenuated vaccine organism,VO:0000506,vaccine organism,organism,('vaccine organism' and 'has quality' some 'vaccine organism live attenuated'),,,vaccine organism live attenuated,,,,,,,,a vaccine organism that is live and attenuated,,Oliver He,,,,
VO:0000368,live vaccine organism,VO:0000506,vaccine organism,organism,('vaccine organism' and 'has quality' some 'vaccine organism live'),,,vaccine organism live,,,,,,,,a vaccine organism that is live,,Oliver He,,,,
VO:0000395,inactivated vaccine organism,VO:0000506,vaccine organism,organism,('vaccine organism' and 'has quality' some 'vaccine organism inactivated'),,,vaccine organism inactivated,,,,,,,,,,Oliver He|Asiyah Yu Lin|Allen Xiang,a vaccine organism that is inactived/killed|killed vaccine organism,,,
VO:0001170,vaccine strain,VO:0000506,vaccine organism,organism,('vaccine organism' and 'has role' some 'vaccine strain role'),,,,vaccine strain role,,,,,,,a vaccine organism that is a specific strain,,Oliver He,,,,
VO:0000544,human vaccinee,VO:0001374,vaccinee,organism,,,,,,,,,human vaccinee,,,a vaccinee that is a human being,,,,,,
VO:0000897,age at vaccination,PATO:0000011,age,quality,,,,,,,,,,,,Age at vaccination is the age of an experiment animal at the time of vaccination.,,Oliver He,,,,
VO:0004921,human age,PATO:0000011,age,quality,,,,,,Homo sapiens,,,,,,,,Anna Maria Masci|Anthony Huffman|Oliver He,,,"The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855.",
VO:0000515,rough phenotype,VO:0000549,bacterial phenotype,quality,,,,,,,,,,,,,,Oliver He,,,,
VO:0000523,smooth phenotype,VO:0000549,bacterial phenotype,quality,,,,,,,,,,,,,,Oliver He,,,,
VO:0000246,edible,VO:0000245,edibility,quality,,,,,,,,,,,,"A quality of edibility that inheres in a bearer by virtue of the bearer being suitable for oral ingestion as food, drug, or vaccine.",,Oliver He,,,This term may be submitted to PATO.,
VO:0000330,inedible,VO:0000245,edibility,quality,,,,,,,,,,,,A quality of edibility that inheres in a bearer by virtue of the bearer being not suitable for oral ingestion.,,Oliver He|Melanie Courtot,,,,
VO:0000805,effective,VO:0000804,effectiveness,quality,,,,,,,,,,,,,,Oliver He,,,,
VO:0000806,ineffective,VO:0000804,effectiveness,quality,,,,,,,,,,,,,,Oliver He,,,,
VO:0000860,vaccine effectiveness,VO:0000804,effectiveness,quality,,,,,,,,,,,,Vaccine effectiveness is an effectiveness associated with a vaccine.,"Hadler TC, et al. Immunization in developing countries. In: Vaccines. Editors: Plotkin S, et al. 2008. p1542-71.",Oliver He,,,,
VO:0000247,vaccine efficacy,PATO:0001029,efficiency,quality,,,,,,,,,,,,"Vaccine efficacy is an efficacy of a vaccine in induction of protective immune response in vivo or protection against infection of a virulent pathogen. 
Specifically, vaccine efficacy (VE) is the percentage reduction in disease incidence attributable to vaccination, calculated by means of the following equation:
VE(%) = (U - V)/U x 100
where U = the incidence in unvaccinated people and 
V = the incidence in vaccinated people.
Ref: Hadler TC, et al. Immunization in developing countries. In: Vaccines. Editors: Plotkin S, et al. 2008. p1542-71.",,Oliver He,,,,
VO:0000456,protection efficacy,PATO:0001029,efficiency,quality,,,,,,,,,,,,"Protection efficacy is an efficiency that is associated with protection by a biological product (e.g., vaccine) against a disease.",,Oliver He,,,,
VO:0000129,vaccination frequency,PATO:0000044,frequency,quality,,,,,,,,,,,,Vaccination frequency is a qualitative term that represents how many times vaccination has occurred.,,Oliver He,,,,
VO:0000815,monthly,PATO:0000044,frequency,quality,,,,,,,,,,,,,,Oliver He,,,,
VO:0000816,biweekly,PATO:0000044,frequency,quality,,,,,,,,,,,,,,Oliver He,,,,
VO:0004922,child age,VO:0004921,human age,quality,,,,,,,,,,,,,,Anna Maria Masci|Anthony Huffman|Oliver He,,,"The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855.",
VO:0004923,adolescence age,VO:0004921,human age,quality,,,,,,,,,,,,,,Anna Maria Masci|Anthony Huffman|Oliver He,,,"The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855.",
VO:0004924,adult age,VO:0004921,human age,quality,,,,,,,,,,,,,,Anna Maria Masci|Anthony Huffman|Oliver He,,,"The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855.",
VO:0004925,senior age,VO:0004921,human age,quality,,,,,,,,,,,,,,Anna Maria Masci|Anthony Huffman|Oliver He,,,"The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855.",
VO:0001373,immunized by vaccination with a licensed vaccine,VO:0000151,immunized,quality,,,,,,,,,,,,"an organismal quality that indicates an organism (e.g., human) is immunized against a disease through vaccination with a licensed vaccine.",,Oliver He,,,,
VO:0000151,immunized,PATO:0001995,organismal quality,quality,,,,,,,,,,,,"an organismal quality that indicates an organism (e.g., human) is immunized against a disease.",,Oliver He|Asiyah Yu Lin,,"To assign the state of 'immunized', we will need to do some assay to measure indicators of immunity, e.g., antibody titers in serum samples.",,
VO:0001372,unimmunized,PATO:0001995,organismal quality,quality,,,,,,,,,,,,"an organismal quality that indicates an organism (e.g., human) is not yet immunized against a disease.",,Oliver He,,,,
VO:0001376,vaccinated,PATO:0001995,organismal quality,quality,,,,,,,,,,,,"an organismal quality that indicates an organism (e.g., human) is vaccinated with a vaccine.",,Oliver He,,,,
VO:0001377,unvaccinated,PATO:0001995,organismal quality,quality,,,,,,,,,,,,"an organismal quality that indicates an organism (e.g., human) is unvaccinated with any vaccine.",,Oliver He,,,,
VO:0000245,edibility,PATO:0001241,physical object quality,quality,,,,,,,,,,,,"A physical quality inhering in a bearer by virtue of the bearer being fit
to be eaten.",,Oliver He|Melanie Courtot,,"Melanie has submitted this term and its two subclasses to obo:
http://sourceforge.net/tracker/?func=detail&aid=2873643&group_id=76834&atid=595654",,
VO:0000549,bacterial phenotype,PATO:0001018,physical quality,quality,,,,,,,,,,,,,,Oliver He,,,,
VO:0000804,effectiveness,PATO:0001018,physical quality,quality,,,,,,,,,,,,"Effectiveness is physical quality that represents the capability of a single physical entity (e.g., vaccine) producing an effect (e.g, protection against a disease).",,Oliver He,,,,
VO:0001379,unvaccinated with a licensed vaccine,VO:0001377,unvaccinated,quality,,,,,,,,,,,,a unvaccinated quality that indicates an organism has not been vaccinated with a licensed vaccine.,,Oliver He,,,,
VO:0001378,vaccinated with a licensed vaccine,VO:0001376,vaccinated,quality,,,,,,,,,,,,a vaccinated quality that indicates an organism is vaccinated with a licensed vaccine.,,Oliver He,,,,
VO:0001148,no vaccine protection,VO:0000247,vaccine efficacy,quality,,,,,,,,,,,,,,Oliver He|Allen Xiang,,,,
VO:0001149,significant vaccine protection,VO:0000247,vaccine efficacy,quality,,,,,,,,,,,,,,Oliver He|Allen Xiang,,,,
VO:0001150,enhanced significant protection,VO:0000247,vaccine efficacy,quality,,,,,,,,,,,,,,Oliver He|Allen Xiang,,,,
VO:0000211,vaccine organism inactivated,VO:0001139,vaccine organism viability,quality,,,,,,,,,,,,an organismal quality of a whole organism vaccine where the whole organism is inactivated/killed and lacks the capability of replication. ,,Oliver He,vaccine organism killed,,,
VO:0001145,vaccine organism live,VO:0001139,vaccine organism viability,quality,,,,,,,,,,,,vaccine being viable is a vaccine viability that indicates a vaccine uses live organism.,,Oliver He|Allen Xiang,,,,
VO:0001139,vaccine organism viability,PATO:0000169,viability,quality,,,,,,,,,,,,vaccine viability is a viability of a vaccine organism.,,Oliver He|Allen Xiang,,,,
VO:0000162,vaccine organism avirulent,PATO:0002146,virulence,quality,,,,,,,,,,,,a virulence of vaccine organism that shows an avirulent pheontype of the organism as the major component of a vaccine. The avirulence means that an vaccine organism is not virulent and does not cause pathogenic phenotype in a host organism.,,Oliver He,,,,
VO:0000173,vaccine organism live attenuated,PATO:0002146,virulence,quality,,,,,,,,,,,,a virulence of vaccine organism that shows an attenuated pheontype of the organism as the major component of a vaccine.,,Oliver He,,,,
VO:0000612,vaccine organism virulent,PATO:0002146,virulence,quality,,,,,,,,,,,,a virulence of vaccine that shows a virulent pheontype of the organism as the major component of a vaccine. The virulent phenotype means that an vaccine organism is virulent and is able to cause a pathogenic phenotype in a host organism.,,Oliver He,,,,
VO:0000621,laboratory animal model of vaccine research,VO:0000616,animal model of vaccine research,role,,,,,,,,,,,,"Animal model of vaccine research is a role played by some organism (e.g., mouse) that is used for vaccine research in the laboratory.",,Oliver He,,,,
VO:0000140,agglutinating antibody role,VO:0000148,antibody role,role,,,,,,,,,,,,,,Oliver He,,,,
VO:0000397,neutralizing antibody role,VO:0000148,antibody role,role,,,,,,,,,,,,,,Oliver He,,,,
VO:0000457,protective antigen role,OBI:0000237,antigen role,role,,,,,,,,,,,,An antigen that stimulates protective immunity when used in vivo.,,Oliver He,,,,
VO:0000812,USA licensed vaccine role,VO:0000630,licensed vaccine role,role,,,,,,,,,,,,a licensed vaccine role that indicates the vaccine occurs in USA.,,Oliver He,,,,
VO:0000864,Canada licensed vaccine role,VO:0000630,licensed vaccine role,role,,,,,,,,,,,,a licensed status that occurs in Canada.,,Oliver He,,,,
VO:0000148,antibody role,BFO:0000023,role,role,,,,,,,,,,,,,,Oliver He,,,,
VO:0000441,vaccine candidate role,BFO:0000023,role,role,,,,,,,,,,,,"Role of a material entity in an investigation, which has not been experimentally or clinically verified to induce a protection or treatment in vivo in a recipient organism. ",,Bjoern Peters|Oliver He,,"This role should be a subclass of 'test substance role', which will be mireoted from OBI by OntoFox.",,
VO:0000615,vaccine role,BFO:0000023,role,role,,,,,,,,,,,,Role that inheres in a prepared material entity that is designed to induce protection or treatment for a disease or infection. ,,Oliver He,,,,
VO:0000616,animal model of vaccine research,BFO:0000023,role,role,,,,,,,,,,,,"Animal model of vaccine research is a role played by some organism (e.g., mouse) that is used for vaccine research.",,Oliver He,,,,
VO:0000617,vaccine component role,BFO:0000023,role,role,,,,,,('part of' some vaccine),,,,,,A role that inheres in a material entity that becomes an ingredient of a vaccine. ,,Oliver He,,,,
VO:0001275,immunization target role,BFO:0000023,role,role,,,,,,,,,,,,"A role that represents a target (i.e., some disorder) of immunization.",,Oliver He|Allen Xiang,,,,
VO:0001361,virmugen role,BFO:0000023,role,role,,,,,,,,,,,,"a role that is inherenced in a gene that can be mutated in a virulent pathogen, leading to an attenuated strain serving as a live attenuated vaccine strain.",,Oliver He|Asiyah Yu Lin,,,,
VO:0005272,TLR7 receptor role,BFO:0000023,role,role,,,,,,,,,,,,A role of a material entity that binds to TLR7 and activates the receptor for pathogen recognition and activation of innate immunity.,https://en.wikipedia.org/wiki/TLR7,Oliver He,Toll-like receptor 7 agonist role,TLR7 agonist role,,
VO:0005274,Th1 immunity stimulatory role,BFO:0000023,role,role,,,,,,,,,,,,,https://en.wikipedia.org/wiki/T_helper_cell,,,,,
VO:0005275,Th2 immunity stimulatory role,BFO:0000023,role,role,,,,,,,,,,,,,https://en.wikipedia.org/wiki/T_helper_cell,,,,,
VO:0005304,TLR4 receptor role,BFO:0000023,role,role,,,,,,,,,,,,A role of a material entity that binds to TLR4 and activates the receptor for pathogen recognition and activation of innate immunity.,https://en.wikipedia.org/wiki/TLR4,Oliver He|Amogh Madireddi,Toll-like receptor 4 agonist role,TLR4 agonist role,,
VO:0005305,TLR3 receptor role,BFO:0000023,role,role,,,,,,,,,,,,A role of a material entity that binds to TLR3 and activates the receptor for pathogen recognition and activation of innate immunity.,https://en.wikipedia.org/wiki/TLR3,Oliver He|Amogh Madireddi,Toll-like receptor 3 agonist role,TLR3 agonist role,,
VO:0005306,TLR8 receptor role,BFO:0000023,role,role,,,,,,,,,,,,A role of a material entity that binds to TLR8 and activates the receptor for pathogen recognition and activation of innate immunity.,https://en.wikipedia.org/wiki/TLR8,Oliver He|Amogh Madireddi,Toll-like receptor 8 agonist role,TLR8 agonist role,,
VO:0005307,TLR2 receptor role,BFO:0000023,role,role,,,,,,,,,,,,A role of a material entity that binds to TLR2 and activates the receptor for pathogen recognition and activation of innate immunity.,https://en.wikipedia.org/wiki/TLR2,Oliver He|Amogh Madireddi,Toll-like receptor 2 agonist role,TLR2 agonist role,,
VO:0005378,NLRP3 receptor role,BFO:0000023,role,role,,,,,,,,,,,,A role of a material entity that binds to NLRP3.,https://en.wikipedia.org/wiki/NLRP3,Oliver He,,,,
VO:0000692,peptide vaccine role,VO:0000624,subunit vaccine role,role,,,,,,,,,,,,A subunit vaccine role that indicates the vaccine being a peptide vaccine. ,,Jie Zheng,,,,
VO:0001274,vaccine recipient role,OBI:0000444,target of material addition role,role,,immunization,,,,organism,,,,immunization,,Role that inheres in an organism that is the target of a vaccine administration (vaccination process).,,Oliver He|Allen Xiang|Barry Smith|Jie Zheng|Anna Maria Masci,,,,https://github.com/vaccineontology/VO/issues/677
VO:0000194,FDA licensed vaccine role,VO:0000812,USA licensed vaccine role,role,,,,,,,,,,,,a USA licensed vaccine role that inheres ina vaccine approven to be by the US FDA to be used for humans in the USA. ,,Oliver He,,,,
VO:0000439,USDA licensed vaccine role,VO:0000812,USA licensed vaccine role,role,,,,,,,,,,,,a USA licensed vaccine role that indicates the vaccine is for veterinary uses.,,Oliver He,,,,
VO:0000147,vaccine adjuvant role,VO:0000415,vaccine additive role,role,,,,,,,,,,,,an adjuvant role that inheres in a vaccine component which is added as part of a vaccine and induces enhanced adaptive immune response to the vaccine antigen. ,,Oliver He,,,"The Latin ""adjuvans"" means to help, particularly to reach a goal.

Adjuvant therapy for cancer is surgery followed by chemotherapy or radiation to help decrease the risk of the cancer recurring (coming back).

An adjuvant is a substance that helps and enhances the pharmacological effect of a drug or increases the ability of an antigen to stimulate the immune system.",
VO:0000885,vaccine preservative role,VO:0000415,vaccine additive role,role,,,,,,,,,,,,"a role inhers in a vaccine component that when added into a vccine formmulation, it can prevent the growth of bacteria or fungi that inadvertently may be introduced into the vaccine during administrating process or the manufacturing process.","P73 Chapter 6, Vaccine 5th edition by Plotkin, S. et al.",Oliver He|Asiyah Yu Lin,,,"The CFR requires that, with certain defined exceptions, preservatives must be added to mulitdose vials of vaccine. (P73 Chapter 6, Vaccine 5th edition by Plotkin, S. et al.)",
VO:0003025,vaccine emulsifier role,VO:0000415,vaccine additive role,role,,,,,,,,,,,,"a role inheres in the vaccine component when it is added into vaccine's formulation, it tends to stabilizes an emulsion by increasing its kinetic stablity.",,Asiyah Yu Lin,,,,
VO:0003026,vaccine stabilizer role,VO:0000415,vaccine additive role,role,,,,,,,,,,,,"a role inheres in vaccine component when added into vaccine's formulation, it tends to inhibit the reaction between two or more other vaccine substances in the final vaccine formulation; it also helps to protect the vaccine from adverse conditions such as the freeze-drying process or heat.",,Asiyah Yu Lin,,,,
VO:0000622,vaccine protective antigen role,VO:0000618,vaccine antigen role,role,,,,,,,,,,,,a vaccine antigen role that inheres in a vaccine antigen which is capable of inducing protective immunity. ,,Oliver He,,,,
VO:0000145,recombinant vaccine vector role,VO:0003439,vaccine vector role,role,,,,,,,,,,,,A vaccine vector role that inheres in a recombinant vaccine vector as a vaccine component. The combination of a recombinant vaccine vector and a heterogenous protective antigen(s) inserted inside the vector for a recombinant vector vaccine. ,,Oliver He|Asiyah Yu Lin,,,,
VO:0000415,vaccine additive role,VO:0000617,vaccine component role,role,,,,,,,,,,,,"A role inheres in a material entity, that has been added into a vaccine's formulation by the manufacture for a specific purpose. For example: adjuvant to enhance the effect of immunogen, perservatives, stablizers and those materials added for affecting PH and isotonicity.","Page 73, Chapter 6, Vaccine, 5th Edition. EXPERT CONSULT by Plotkin SA., et. al. 2008",Asiyah Yu Lin|Oliver He,,,,
VO:0000618,vaccine antigen role,VO:0000617,vaccine component role,role,,,,,,,,,,,,,,Oliver He,,,,
VO:0003050,vaccine conjugate role,VO:0000617,vaccine component role,role,,,,,,,,,,,,A role inheres in a material eneitity that union itself chemically with a relative weak vaccine antigen to form a new whole that can create an effective miinuogen. The ,,Asiyah Yu Lin,,,,
VO:0003439,vaccine vector role,VO:0000617,vaccine component role,role,,,,,,,,,,,,Vaccine component role inheres in a vaccine vector.,,Jie Zheng,,,,
VO:0000137,combination vaccine role,VO:0000615,vaccine role,role,,,,,,,,,,,,A vaccine role that indicates the vaccine being a combination vaccine. ,,Oliver He,,,,
VO:0000208,vaccine in research role,VO:0000615,vaccine role,role,,,,,,,,,,,,"A vaccine role that is not licensed or in clinical trial; instead, it has been experimently approved to induce protection or treatment effect in vivo in at least an experimental animal model. ",,Oliver He,,,,
VO:0000504,whole organism vaccine role,VO:0000615,vaccine role,role,,,,,,,,,,,,a vaccine role that indicates the vaccine being a whole organism vaccine. ,,Oliver He,,,,
VO:0000623,DNA vaccine role,VO:0000615,vaccine role,role,,,,,,,,,,,,A vaccine role that indicates the vaccine being a DNA vaccine. ,,Oliver He,,,,
VO:0000624,subunit vaccine role,VO:0000615,vaccine role,role,,,,,,,,,,,,A vaccine role that indicates the vaccine being a subunit vaccine. ,,Oliver He,,,,
VO:0000625,conjugate vaccine role,VO:0000615,vaccine role,role,,,,,,,,,,,,A vaccine role that indicates the vaccine being a conjugate vaccine. ,,Oliver He,,,,
VO:0000630,licensed vaccine role,VO:0000615,vaccine role,role,,,,,,,,,,,,A licensed vaccine role is a regulation-assigned role that indicates that a vaccine obtains official approval for commercial production and selling on the market.,,Oliver He,,,,
VO:0000631,vaccine in clinical trial role,VO:0000615,vaccine role,role,,,,,,,,,,,,A vaccine in clinical trial role is a regulation-assigned role that inheres in a vaccine that is currently in clinical trial.,,Oliver He,,"In medical research, clinical trials are conducted to allow safety and efficacy data to be collected for new drugs or devices.",,
VO:0000636,recombinant vector vaccine role,VO:0000615,vaccine role,role,,,,,,,,,,,,A vaccine role that indicates the vaccine being a recombinant vector vaccine. ,,Oliver He,,,,
VO:0000728,RNA vaccine role,VO:0000615,vaccine role,role,,,,,,,,,,,,A vaccine role that indicates the vaccine being a RNA vaccine. ,,Oliver He,,,,
VO:0000807,toxoid vaccine role,VO:0000615,vaccine role,role,,,,,,,,,,,,A vaccine role that indicates the vaccine being a toxoid vaccine. ,,Oliver He,,,,
VO:0001182,vaccine strain role,VO:0000615,vaccine role,role,,,,,,,,,,,,a vaccine role that is borne by an organism strain serving as a vaccine,,Oliver He,,,,
VO:0004913,virus-like particle vaccine role,VO:0000615,vaccine role,role,,,,,,,,,,,,"A vaccine role that inheres in a vaccine using virus-like particles (VLPs), multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccines.",https://pubmed.ncbi.nlm.nih.gov/20923267/,Anthony Huffman|Oliver He,virus like particle vaccine role,,,
VO:0010393,vaccine monovalent role,VO:0000615,vaccine role,role,,,,,,,,,,,,A vaccine that is designed to immunize against a single antigen or single strain of a pathogen.,,Jie Zheng|Xingxian Li,,,,
VO:0010394,vaccine multivalent role,VO:0000615,vaccine role,role,,,,,,,,,,,,A vaccine that is designed to immunize against multiple antigen or multiple strain of a pathogen.,,Jie Zheng|Xingxian Li,,,,
VO:0007747,authorized vaccine role,VO:0000615,vaccine role,role,,,,,,,,,,,,Vaccine role that indicates a vaccine has received emergency use authorization (EUA) from regulatory authorities for distribution and administration to the public.,,Jie Zheng,,,,
VO:0000350,live virulent vaccine role,VO:0000615,vaccine role,role,,,,,,,,,,,,Vaccine role that is characteristic of a live virulent vaccine. ,,Jie Zheng,,,,
VO:0010008,inactivated vaccine role,VO:0000615,vaccine role,role,,,,,,,,,,,,Vaccine role that is characteristic of an inactivated vaccine. ,,Jie Zheng,,,,
VO:0010038,live attenuated vaccine role,VO:0000615,vaccine role,role,,,,,,,,,,,,Vaccine role that is characteristic of a live attenuated vaccine. ,,Jie Zheng,,,,
VO:0000426,period of persistence of vaccine induced immune response,BFO:0000038,one-dimensional temporal region,temporal region,,,,,,,,,,,,period of persistence of vaccine induced immune response is a temporal interval during which a vaccine-induced immune response continuously exists. This term is related to the process 'persistence of vaccine induced immune response'.,,Oliver He|Melanie Courtot,,,,
VO:0000540,time of survival of live vaccine inside host,BFO:0000038,one-dimensional temporal region,temporal region,,,,,,,,,,,,time of survival of live vaccine inside host is a temporal interval during which a live vaccine survives inside a host organism. This entity is related to the process survival of live vaccine inside host.,,Oliver He|Melanie Courtot,,,,